Clinical Trials on Not Condition Specific in Singapore

Total 3082 results

AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Active, not recruiting

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
Boehringer Ingelheim
Bayer; GlaxoSmithKline

Completed

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Stroke

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, El Salvador, Finland, France, Germany, Greece, Hong Kong, India, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, No... and more
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
AstraZeneca

Terminated

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

Type 2 Diabetes

United States, Brazil, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Vietnam, Germany, Philippines, Malaysia, Sweden, Estonia, Latvia, Lithuania, Finland, Norway and more
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

Heart Failure With Preserved Ejection Fraction

China, Germany, United States, Colombia, South Africa, Italy, Austria, Belgium, Croatia, Romania, Taiwan, Japan, Netherlands, Denmark, France, Israel, Spain, Switzerland, Korea, Republic of, Argentina, Canada, United Kingdom, Bulgaria, Gree... and more
Novartis Pharmaceuticals

Terminated

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) (ALTITUDE)

Cardiovascular Disease | Type 2 Diabetes Mellitus

Spain, China, United States, Belgium, Colombia, South Africa, Italy, United Kingdom, Germany, Hungary, Japan, Taiwan, Turkey, Netherlands, Greece, Switzerland, Austria, France, Thailand, Argentina, Canada, Singapore, Lithuania, Sweden, ... and more
Janssen Research & Development, LLC
Bristol Myers Squibb Company (BMS)

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)

Ischemic Stroke; Ischemic Attack, Transient

Italy, United States, Hong Kong, Japan, Taiwan, South Africa, Korea, Republic of, Israel, United Kingdom, Argentina, Belgium, New Zealand, Canada, Germany, Czechia, Denmark, Mexico, Croatia, France, Australia, Brazil, China, Hungary, ... and more
Novo Nordisk A/S

Recruiting

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

Heart Failure

Korea, Republic of, Belgium, United States, Australia, Italy, China, Latvia, United Kingdom, Croatia, Spain, Netherlands, Serbia, Malaysia, Israel, Austria, Singapore, Thailand, Hungary, Argentina, Japan, Taiwan, Turkey, Germany, South... and more
Eli Lilly and Company
Duke Clinical Research Institute; Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS)

Acute Coronary Syndrome

Argentina, Brazil, Canada, Italy, China, Puerto Rico, Australia, Romania, Russian Federation, France, Germany, United States, Belgium, Bulgaria, Poland, Ukraine, United Kingdom, Colombia, Hungary, Philippines, Croatia, Denmark, India, Chil... and more
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Boehringer Ingelheim
Uppsala University; Population Health Research Institute

Completed

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Stroke | Atrial Fibrillation

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, N... and more
AstraZeneca

Completed

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO)

Acute Coronary Syndrome

Sweden, United States, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Turkey, United Kingdom, Germany, Philippines, China, Hungary, Romania, Denmark, Netherlands, Norway, C... and more
CSL Behring

Completed

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Acute Coronary Syndrome

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvi... and more
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
Boehringer Ingelheim

Completed

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Latv... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Atherosclerotic Cardiovascular Disease

United States, China, South Africa, Spain, Austria, Belgium, Croatia, Estonia, Hungary, Taiwan, Turkey, Netherlands, Italy, Australia, Czechia, Denmark, France, Israel, Korea, Republic of, Thailand, Argentina, Bulgaria, Greece, Romania, Sloveni... and more
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)

Heart Failure With Reduced Ejection Fraction

China, Germany, United States, Colombia, Korea, Republic of, Romania, South Africa, Canada, Belgium, Estonia, Hungary, Italy, Russian Federation, Taiwan, Turkey, United Kingdom, Spain, France, Netherlands, Hong Kong, Bulgaria, Israel and more
Bristol-Myers Squibb

Completed

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

Atrial Fibrillation | Atrial Flutter

Australia, Brazil, China, France, Germany, India, Italy, Korea, Republic of, Mexico, Russian Federation, Sweden, Taiwan, Turkey, United States, Hong Kong, Spain, Argentina, Canada, Puerto Rico, Colombia, Denmark, Austria, Belgium, Hun... and more
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Dyslipidemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Czechia, Hungary, Taiwan, Colombia, Poland, Russian Federation, Switzerland, Korea, Republic of, Mexico, ... and more
Bristol-Myers Squibb
Pfizer; Duke Clinical Research Institute

Terminated

Phase III Acute Coronary Syndrome (APPRAISE-2)

Acute Coronary Syndrome

Argentina, China, India, Japan, Korea, Republic of, Mexico, Poland, South Africa, Sweden, United States, Chile, Spain, United Kingdom, Australia, Brazil, Colombia, Austria, Denmark, Germany, Belgium, Hungary, Israel, Peru, Romania, Russian... and more
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Novartis Pharmaceuticals
National Cancer Institute (NCI); Canadian Cancer Trials Group; North Central... and other collaborators

Completed

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (ALTTO)

Neoplasms, Breast

United States, Belgium, France, Spain, United Kingdom, Croatia, Estonia, India, Italy, Canada, Netherlands, Argentina, Australia, Austria, Czechia, Denmark, Germany, Israel, Japan, Norway, Poland, Russian Federation, Switzerland, Taiwan, Korea, Republic... and more
Bayer

Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF)

Atrial Fibrillation | Prevention of Stroke or Systemic Embolism

Canada, United States, Israel, Korea, Republic of, China, Taiwan, Belgium, Australia, Singapore, Malaysia, Slovakia, United Kingdom, Czechia, Latvia, Japan, Brazil, Lithuania, Germany, France, Sweden, Turkey, Switzerland, Estonia, Bul... and more
Novartis Pharmaceuticals

Recruiting

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Primary Prevention of Atherosclerotic Cardiovascular Disease

United States, China, Italy, Spain, France, Netherlands, Poland, Switzerland, Taiwan, Greece, Thailand, Brazil, India, Hungary, Latvia, Mexico, Israel, Malaysia, Turkey, Argentina, Singapore, Australia, Belgium, Bulgaria, Denmark, Croatia, South... and more
Sanofi
Regeneron Pharmaceuticals

Completed

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Atherosclerotic Cardiovascular Disease

China, Hong Kong, Austria, Bulgaria, Norway, Peru, France, Japan, Spain, Lithuania, Philippines, Israel, Belgium, Croatia, Poland, Hungary, Chile, Mexico, Latvia, Singapore, Switzerland, Colombia, Greece, Ukraine, Turkey, Finland, United States and more
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Colombia, Israel, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic... and more

Clinical Trials on Not Condition Specific in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations